Events Archives - Page 8 of 9 - Telix Pharmaceuticals Limited

Industry Leaders’ Round-Table at SNMMI Mid-Winter Satellite Symposium

Telix CEO, Dr Christian Behrenbruch recently facilitated an international expert panel discussion at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Mid-Winter Symposium entitled: “Ga-68 PSMA-11: Advances in Technology, Demand & Supply”.

Telix Presentation at the European Multidisciplinary Congress on Urological Cancers

Telix recently presented at the 12th European Multidisciplinary Congress on Urological Cancers entitled: “New Perspectives in Prostate and Kidney Cancer”.

Telix presentations at European Association of Nuclear Medicine 2020 Satellite Symposium

Telix sponsored a session at the recent EANM20 Satellite Symposium, entitled “Next Generation Imaging with PSMA-PET & More”. For those unable to attend, we are pleased to provide recordings of live presentations held on 29th October 2020.

Telix Japan to Present at Japanese Society of Nuclear Medicine Annual Scientific Meeting

Telix Japan is pleased to announce it will be presenting at the Annual Scientific Meeting of the Japanese Society of Nuclear Medicine (JSNM-JSNMT2020) to be held 12-14th November 2020 at Kobe International Conference Center.

Telix to Present at European Association of Nuclear Medicine 2020 Annual Congress

Telix sponsored a session at the recent EANM20 Satellite Symposium, entitled “Next Generation Imaging with PSMA-PET & More”. For those unable to attend, we are pleased to provide recordings of live presentations held on 29th October 2020.

Telix Pharmaceuticals to Participate at AusBiotech + Invest 2020

Telix Pharmaceuticals is pleased to announce we are participating at AusBiotech + Invest 2020 online conference to be held live 28th – 30th October 2020 and on-demand. Telix is pleased to be sponsoring the “Radiopharmaceuticals drug development: current and future trends” session on Thursday 29th October 2.15 pm – 3.00 pm (AEST).

Presentation to Jefferies Virtual Healthcare Conference

Telix Pharmaceuticals Limited has today announced that Group CBO Dr. David Cade presented at Jefferies Virtual Healthcare Conference

Telix presents IPAX-1 study in glioblastoma treatment at ASCO 2020

Telix Pharmaceuticals is pleased to announce that the IPAX-1 study will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program to be held May 29 – 31, 2020. IPAX-1 is a Phase 1/2 clinical study of TLX101 (also known as 131I-IPA or 4-L-[131I]iodo-phenylalanine) for patients with recurrent glioblastoma multiforme (GBM).

Telix Supports Molecular Imaging Summer Program at MSKCC

Telix Pharmaceuticals Ltd is pleased to announce our support of the Molecular Imaging Summer Program at MSKCC

Webcast of CEO’s presentation to Jefferies 2019 London Healthcare Conference

Telix Pharmaceuticals Limited is pleased to announce that Group CEO, Dr. Christian Behrenbruch, presented at Jefferies 2019 London Healthcare Conference.